enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of “Hold” by Brokerages

by · The Cerbat Gem

Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) have been given an average rating of “Hold” by the fourteen ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $12.6818.

Several brokerages have weighed in on ENGN. Morgan Stanley lowered enGene from an “overweight” rating to an “equal weight” rating in a report on Friday, May 8th. Guggenheim lowered enGene from a “buy” rating to a “neutral” rating in a report on Thursday, May 7th. Leerink Partners lowered enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price objective for the company. in a report on Friday, May 8th. UBS Group reduced their price objective on enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Finally, Citizens Jmp lowered enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th.

Check Out Our Latest Report on enGene

enGene Price Performance

Shares of NASDAQ ENGN opened at $1.62 on Tuesday. The stock has a fifty day simple moving average of $4.41 and a two-hundred day simple moving average of $7.24. enGene has a 1-year low of $1.40 and a 1-year high of $12.25. The firm has a market cap of $108.52 million, a price-to-earnings ratio of -0.72 and a beta of -0.30. The company has a current ratio of 11.75, a quick ratio of 11.75 and a debt-to-equity ratio of 0.09.

Institutional Investors Weigh In On enGene

Institutional investors have recently made changes to their positions in the stock. Cresset Asset Management LLC purchased a new stake in shares of enGene during the second quarter worth $36,000. Raymond James Financial Inc. lifted its position in shares of enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares in the last quarter. Paloma Partners Management Co purchased a new stake in shares of enGene during the second quarter worth $38,000. PFS Partners LLC lifted its position in shares of enGene by 22.2% during the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Hudson Bay Capital Management LP purchased a new stake in shares of enGene during the third quarter worth $76,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Recommended Stories